GB202216575D0 - Canine parvovirus nanobody CPV-VHH-D4 and application thereof - Google Patents

Canine parvovirus nanobody CPV-VHH-D4 and application thereof

Info

Publication number
GB202216575D0
GB202216575D0 GBGB2216575.7A GB202216575A GB202216575D0 GB 202216575 D0 GB202216575 D0 GB 202216575D0 GB 202216575 A GB202216575 A GB 202216575A GB 202216575 D0 GB202216575 D0 GB 202216575D0
Authority
GB
United Kingdom
Prior art keywords
cpv
nanobody
vhh
application
canine parvovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2216575.7A
Other versions
GB2608978A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Animal Science of CAAS
Original Assignee
Institute of Animal Science of CAAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Animal Science of CAAS filed Critical Institute of Animal Science of CAAS
Publication of GB202216575D0 publication Critical patent/GB202216575D0/en
Publication of GB2608978A publication Critical patent/GB2608978A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GB2216575.7A 2021-11-12 2022-11-07 Canine parvovirus nanobody CPV-VHH-D4 and application thereof Pending GB2608978A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111337112.2A CN113861286B (en) 2021-11-12 2021-11-12 Canine parvovirus nano antibody CPV-VHH-D4 and application thereof

Publications (2)

Publication Number Publication Date
GB202216575D0 true GB202216575D0 (en) 2022-12-21
GB2608978A GB2608978A (en) 2023-01-18

Family

ID=78984435

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2216575.7A Pending GB2608978A (en) 2021-11-12 2022-11-07 Canine parvovirus nanobody CPV-VHH-D4 and application thereof

Country Status (2)

Country Link
CN (1) CN113861286B (en)
GB (1) GB2608978A (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223029A1 (en) * 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
CN103665152B (en) * 2013-12-02 2016-01-20 山西农业大学 Canine parvovirus single domain antibody and its preparation method and application
CN109369803B (en) * 2018-09-07 2021-05-04 深圳市国创纳米抗体技术有限公司 Anti-rabies virus G protein nano antibody and application thereof
CN109212230B (en) * 2018-09-12 2021-11-30 东北农业大学 Sensitized polystyrene nano-microsphere for detecting canine parvovirus structural protein VP2 antibody and preparation method and application thereof
US20220064224A1 (en) * 2018-11-13 2022-03-03 Novobind Livestock Therapeutics, Inc. Antibodies against disease causing agents of canines and felines and uses thereof
CN109627331B (en) * 2019-01-22 2022-03-29 长春西诺生物科技有限公司 Heavy chain and light chain variable regions of anti-canine parvovirus antibody and genetic engineering antibody
CN113336843B (en) * 2020-03-02 2022-04-05 北京市农林科学院 Single-chain antibody for resisting canine parvovirus disease and preparation method thereof

Also Published As

Publication number Publication date
CN113861286A (en) 2021-12-31
CN113861286B (en) 2022-10-25
GB2608978A (en) 2023-01-18

Similar Documents

Publication Publication Date Title
EP3713406A4 (en) Endonuclease sexing and sterilization in insects
GB202106282D0 (en) Composition and use thereof
EP4096664A4 (en) Compounds and uses thereof
EP3604423A4 (en) Thermoplastic elastomer composition and use thereof
EP4096651A4 (en) Compounds and uses thereof
SG11202107498VA (en) Haloallylamine compounds and application thereof
SG11202103103TA (en) Gdsl lipase, genetically-engineered bacteria and application thereof
EP4097096A4 (en) Compounds and uses thereof
IL270898A (en) Low-alcohol and sterilizable antimicrobial compositions and use thereof
EP4063489A4 (en) Composition and use thereof
EP4100031A4 (en) Microbial combinations and uses thereof
EP4096668A4 (en) Compounds and uses thereof
SG11202102182VA (en) Desiccant composition and use thereof
GB202216575D0 (en) Canine parvovirus nanobody CPV-VHH-D4 and application thereof
EP3573611A4 (en) Amide compounds and use thereof
PL3579696T3 (en) In vivo model for parasitic worm infection and methods for evaluating antiparasitic compounds, including compounds active against canine heartworm
IL276984A (en) Insecticidal composition and use thereof
EP4134068A4 (en) Bendamustine composition and use thereof
IL304222A (en) Substituted pyridotriazine compounds and uses thereof
IL311521A (en) Egfrviii-targeted compounds and uses thereof
ZA202102065B (en) Solid composition for agricultural and veterinary use
EP4072998A4 (en) Nanostructured binary gel composition and use thereof
GB202215746D0 (en) Terpenophenolic compounds and their use
GB202104122D0 (en) Compounds and their use
EP4126844A4 (en) Amide compounds and uses thereof